Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.
about
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States.Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.
P2860
Q30279214-372F9F79-10EA-45D0-A036-1E37F45BF303Q36394528-9FB97851-BB3A-493C-BDD4-19536494DA79Q36568921-1E0DE488-7BD2-4036-9EB1-14C2AA528432Q38162941-8293CE30-83E8-45C0-A9E6-D9651DABD690Q38243024-F81243A2-92CE-471A-AED1-351EE00E4918Q38289267-251A88B9-B85F-4419-98AC-18EAA4B89D34Q41562696-797FA31A-3989-40CA-B6FF-67EABBAC1907
P2860
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Dalfampridine extended release ...... g safety experience in the US.
@en
type
label
Dalfampridine extended release ...... g safety experience in the US.
@en
prefLabel
Dalfampridine extended release ...... g safety experience in the US.
@en
P2093
P2860
P356
P1476
Dalfampridine extended release ...... g safety experience in the US.
@en
P2093
Graham Barker
Herbert R Henney
Michele Jara
P2860
P304
P356
10.2147/NDT.S41596
P407
P577
2013-03-10T00:00:00Z